Revvity Expands Alliance with Genomics England to Research Newborn Genomic Sequencing

Rare Daily Staff

Revvity said it will expand its collaboration with Genomics England to further collaborate on the Generation study, an effort to sequence the genomes of 100,000 newborn babies in England to improve early diagnosis of rare genetic conditions.

Under the new contract, Revvity will provide DNA sequencing services to help screen newborns for rare genetic conditions. This expands on its previous responsibilities of performing DNA extraction services.

Revvity said it will now be able to provide an integrated end-to-end solution with a localized lab facility, which will allow for accelerated extraction and sequencing services to advance the screening process for these rare conditions.

The Generation Study, which Genomics England is leading in partnership with the National Health Service, is aimed at screening newborns for more than 200 rare genetic disorders. The findings will help inform future decisions on using whole genome sequencing in newborn screening.

Such use of genomic screening could help healthcare professionals identify risks for pediatric-onset conditions sooner, enabling earlier interventions and personalized care.

“This collaboration is an important step forward in our mission to generate evidence on the use of genomic sequencing in newborn screening,” said Ellen Thomas, chief medical officer at Genomics England. “By working with Revvity as one of our sequencing partners for the Generation Study, we can integrate sequencing alongside extraction, streamlining the process and generating results more efficiently, helping families get answers and access to care sooner.”